CAS 1865733-40-9: Capmatinib hydrochloride

Description:Capmatinib hydrochloride is a small molecule inhibitor primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) with MET exon 14 mutations. It functions by selectively inhibiting the MET receptor tyrosine kinase, which plays a crucial role in tumor growth and metastasis. The substance is characterized by its ability to bind to the active site of the MET protein, thereby blocking its signaling pathways that promote cancer cell proliferation. Capmatinib hydrochloride is typically administered orally and is known for its favorable pharmacokinetic profile, including good bioavailability and a manageable side effect profile. The hydrochloride salt form enhances its solubility and stability, making it suitable for pharmaceutical formulations. As with many targeted therapies, monitoring for specific biomarkers is essential for patient selection and treatment efficacy. Overall, Capmatinib hydrochloride represents a significant advancement in targeted cancer therapies, offering hope for patients with specific genetic alterations in their tumors.

Synonyms:
Capmatinib 2HCl.H2O
Capmatinib hydrochloride Hydrate
Capmatinib Hydrochloride Hydrate(INCB28060)
See more synonyms

Found 3 products.

Product data	Purity	Price range	Estimated delivery
Capmatinib 2HCl.H2O REF: 54-BUP10841CAS: 1865733-40-9	99.83%	189.00 €~868.00 €	Thu 17 Apr 25
Capmatinib 2HCl.H2O REF: TM-T8825CAS: 1865733-40-9	99.77%	49.00 €~590.00 €	Wed 23 Apr 25
Capmatinib HCl hydrate REF: 3D-QZC73340CAS: 1865733-40-9	Min. 95%	- - -	Discontinued product